BioCentury | Apr 28, 2018

The outsiders

As he retires from Sanofi, Elias Zerhouni has advice for the biopharma industry: the traditional executive mold must be expanded. On April 24, Sanofi announced Zerhouni would retire on June 30 and that John Reed,...
BioCentury | Jan 27, 2018

Growing up Genzyme

The proposed acquisition of Bioverativ Inc. ticks multiple boxes on Sanofi’s to-do list for transforming itself into a top tier pharma, and solidifies the position of its Genzyme unit as the pharma’s growth engine. Olivier...
BC Extra | Oct 17, 2014
Financial News

Dance withdraws IPO

Dance Biopharm Inc. (Brisbane, Calif.) withdrew its proposed IPO on NASDAQ. The diabetes company did not provide a reason in its SEC filing. In April, the company filed to raise up to $75 million in...
BC Extra | Apr 10, 2014
Financial News

Inhalable insulin play Dance files for IPO

Dance Biopharm Inc. (Brisbane, Calif.) filed to raise up to $75 million in an IPO on NASDAQ underwritten by Wells Fargo; Stifel; Oppenheimer; and Roth Capital Partners. Dance is developing Dance 501 (formerly Adagio ),...
BC Week In Review | Oct 21, 2013
Company News

Dance Biopharm, Harmony Asset deal

Dance and Harmony formed a JV to develop and commercialize Dance's Adagio inhaled insulin in China and other Asian countries, excluding Japan. Harmony, which will have majority ownership of the JV, will be responsible for...
BC Week In Review | Aug 19, 2013
Clinical News

Adagio: Phase I/II data

Preliminary data from the Phase I/II Samba 01 trial in 12 Type I diabetics showed that Adagio was safe and well tolerated and did not lead to coughing. Dance Biopharm said Adagio delivered insulin consistently...
BC Week In Review | May 6, 2013
Company News

Dance Pharma Inc., Hikma Pharmaceuticals deal

Hikma received exclusive rights to market Dance Pharma's Dance 01 in the Middle East and Africa to treat diabetes. Dance Pharma plans to start Phase III development of the inhaled insulin product next year. The...
BioCentury | Oct 1, 2012
Product Development

Adagio for Aubagio

When Sanofi 's Genzyme Corp. unit launches multiple sclerosis drug Aubagio teriflunomide this month, its job will be to overcome physician sentiment that the drug's pregnancy restrictions and modest efficacy will relegate it to second-...
BioCentury | Oct 1, 2012

4Q Financial Markets Preview: Wanted: Catalysts for generalists

On the back of a strong multi-quarter run for biotech, buysiders hope a handful of important catalysts from some of the industry's biggest names will continue to attract generalist interest. A steady flow of news...
BC Week In Review | Jan 2, 2012
Company News

Adagio Pharmaceuticals, Cynapsus deal

Cynapsus completed its acquisition of Adagio in a stock deal valued at C$520,000 ($509,340) based on Cynapsus' close of C$0.02 on Dec. 21, the day before the close was announced. Adagio shareholders will receive 26...
Items per page:
1 - 10 of 16